Suchergebnisse - "Meyers, Daniel E"

PubPharm (28)

1

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors

enthalten in: JAMA network open | 2024

von Cook, S. | Samuel, V. | Meyers, D. | +8

2

Characteristics of clinician input in Canadian funding decisions for cancer drugs : a cross-sectional study based on CADTH reimbursement recommendations

enthalten in: BMJ open | 2023

von Jenei, K. | Meyers, D.

3

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors

enthalten in: The oncologist | 2023

von Stukalin, I. | Navani, V. | Gupta, M. | +13

4

Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade

enthalten in: Clinical lung cancer | 2023

von Navani, V. | Meyers, D. | Ruan, Y. | +11

5

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors

enthalten in: JTO clinical and research reports | 2023

von Meyers, D. | Pasternak, M. | Dolter, S. | +9

6

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy

enthalten in: JAMA network open | 2022

von Watson, A. | Goutam, S. | Stukalin, I. | +9

7

Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab

enthalten in: Current oncology (Toronto, Ont.) | 2022

von Goutam, S. | Stukalin, I. | Ewanchuk, B. | +6

8

Industry Relationships With Medical Oncologists : Who Are the High-Payment Physicians?

enthalten in: JCO oncology practice | 2022

von Wright, K. | Meyers, D. | Chisamore, T. | +5

9

Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials-Reply

enthalten in: JAMA oncology | 2022

von Jenei, K. | Meyers, D. | Prasad, V.

CommentOn: JAMA Oncol. 2021 Oct 1;7(10):1569-1570. - PMID 34436541

10

Trends in drug revenue among major pharmaceutical companies : A 2010-2019 cohort study

enthalten in: Cancer | 2022

von Meyers, D. | Meyers, B. | Chisamore, T. | +5